C
Corbus Pharmaceuticals
Home :: Corbus Pharmaceuticals Holdings, Inc. (CRBP)
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of medicines targeting the endocannabinoid system. The company has a diversified portfolio and is committed to helping people defeat serious illnesses, with a focus on oncology and obesity.
Corbus's pipeline includes CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity, and CRB-701 (SYS6002), a next-generation Nectin-4 targeting antibody-drug conjugate (ADC) for the treatment of urothelial cancer. The company is actively enrolling patients in the multiple ascending dose portion of its Phase 1 study for CRB-913 and has had abstracts for CRB-701 accepted for presentation at major medical conferences.
Corbus operates in the biopharmaceutical sector, a market characterized by high research and development costs and long product development cycles. The company's business model is centered on the discovery, development, and subsequent commercialization of its drug candidates. As a clinical-stage company, Corbus does not yet generate revenue from product sales and its financial performance is largely driven by its ability to raise capital to fund its research and development activities.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Norwood, United States
- Listing
- IPO 2014
- Employees
- 59
- Open positions
- 11
- Dealroom signal
- 83.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Oct 2025 | $75M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Feb 2024 | $95M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Corbus Pharmaceuticals is 4.8K monthly website visits, up 20% over the last three months. Corbus Pharmaceuticals's team grew 9.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Boston Harbor Angels
Cystic Fibrosis Foundation
Series A4 investors entered at this stage
Maine Angels
SternAegis Ventures- FAFort Point Angels
Oleg Uritsky
Series B and later3 investors entered at this stage
- DMDafna Capital Management
Perceptive Advisors
K2 HealthVentures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Corbus Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Corbus Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.